The U.S. healthcare payment system was largely built around a model of ongoing, incremental costs — a monthly medication, a periodic procedure, spread across a patient's lifetime and, critically, often across multiple different insurers as patients change jobs and coverage over time. Gene and cell therapies, several now priced above a million dollars for a single one-time treatment, don't fit that model at all — creating genuine financing challenges that insurers, health systems, and manufacturers are still actively working out.
Why the Pricing Reflects More Than List Cost
Manufacturers generally justify gene therapy pricing by pointing to the enormous upfront research, clinical trial, and specialized manufacturing infrastructure investment required, combined with a genuinely small eligible patient population for many gene therapies targeting rare diseases — meaning development costs must be recovered across far fewer treated patients than a mass-market drug. Whether this pricing logic is fair or excessive remains genuinely contested, but the underlying economic reality of small patient populations and massive fixed development costs is not disputed.
The Insurance Coverage Timing Mismatch
A structural problem specific to gene therapy financing: the treatment cost is paid entirely upfront, but the patient may switch health insurance plans — through a job change, moving to Medicare eligibility, or other life transitions — well before the treatment's full long-term value is realized. This creates a genuine misalignment where one insurer bears the entire upfront cost while a different insurer may capture much of the downstream savings from avoided future treatment, a dynamic that has complicated insurer willingness to cover expensive gene therapies as readily as more traditional treatments.
Outcomes-Based and Value-Based Contracts
In response, manufacturers and payers have increasingly structured outcomes-based payment agreements, where a portion of payment is contingent on the treatment actually achieving pre-specified clinical outcomes over a defined follow-up period, with refunds or reduced payment if the treatment fails to deliver the expected benefit. Some agreements structure payment as an installment plan spread over several years rather than a single upfront lump sum, explicitly designed to reduce the immediate budget impact and financial risk concentration for the paying insurer.
The Medicaid and State Budget Challenge
State Medicaid programs face particular strain from gene therapy costs, since Medicaid enrollment tends to skew toward populations with higher prevalence of several conditions gene therapy targets, and state budgets — unlike commercial insurers spreading risk across a larger, more diversified population — face more direct fiscal exposure when a small number of extremely expensive treatments hit a state program in a single budget cycle. Some states have explored multi-state purchasing pools or federal supplemental funding mechanisms specifically to address this concentrated fiscal risk.
Reinsurance and Risk Pooling Innovations
Employer health plans and smaller insurers have increasingly turned to specialized stop-loss reinsurance products specifically covering catastrophic gene therapy claims, spreading the financial risk of an unpredictable, extremely expensive treatment need across a broader risk pool — a financial innovation that has grown specifically in response to the gene therapy pricing reality, rather than existing as a general-purpose insurance product beforehand.
Conclusion
Financing million-dollar, potentially curative one-time treatments represents a genuinely novel challenge that the traditional healthcare payment system wasn't designed to absorb smoothly. The payment innovations emerging — outcomes-based contracts, installment payments, specialized reinsurance — reflect real, ongoing efforts to make transformative but extraordinarily expensive treatments financially sustainable at scale as the gene therapy pipeline continues expanding.
